

FORM 51-102F3
MATERIAL CHANGE REPORT

Item 1: Name and Address of Company

BioMark Diagnostics Inc. (“the Issuer”)
165 – 10551 Shellbridge Way
Richmond, BC V6X 2W8

Item 2: Date of Material Change

June 24, 2016

Item 3: News Release

A news release was issued and disseminated on June 20, 2016 and filed on SEDAR (www.sedar.com). A copy of the news release is attached as Schedule “A” hereto.

Item 4: Summary of Material Change

The issuer announced an increase in the private placement from 4,000,000 to 6,500,000 units at a price of \$0.15 per unit for maximum total proceeds of \$975,000. Each unit consists of one common share of BioMark and one-half of one share purchase warrant. One whole share purchase warrant will entitle the holder thereof to purchase one common share of BioMark at \$0.30 per share for a period of one year from the grant date. The issuer also announced that it has engaged Stockhouse Deal Room in connection with closing the second tranche of its current private placement.

Item 5: Full Description of Material Change

Please see the attached Schedule “A”.

Item 6: Reliance on subsection 7.1(2) of National Instrument 51-102

Note applicable

Item 7: Omitted Information

None

Item 8: Executive Officer

Rashid Ahmed Bux, President & CEO
Telephone: 604.282.6567
Email: info@biomarkdiagnostics.com

Item 9: Date of Report

June 24, 2016

Schedule "A"



165 – 10551 Shellbridge Way
Richmond, BC, V6X 2W8

BIOMARK Engages Stockhouse.com Deal Room with Private Placement

June 20, 2016 - Vancouver, British Columbia - BioMark Diagnostics Inc. ("BioMark" or the "Company") (CSE: BUX) (FSE: 20B) (OTCQB: BMKDF) is pleased to announce it has engaged Stockhouse Deal Room in connection with closing the second tranche of its current private placement.

Private Placement

The private placement was recently increased from 4,000,000 to 6,500,000 units at a price of \$0.15 per unit for maximum total proceeds of \$975,000. Each unit consists of one common share of BioMark and one-half of one share purchase warrant. One whole share purchase warrant will entitle the holder thereof to purchase one common share of BioMark at \$0.30 per share for a period of one year from the grant date. BioMark closed the first tranche of the private placement on March 15, 2016 for proceeds of \$408,954.

The private placement offering will be conducted in the provinces of British Columbia, Alberta, and Quebec to qualified investors under National Instrument 45-106 *Prospectus Exemptions*.

Stockhouse Deal Room

The Stockhouse Private Deal Room is a portal for qualified investors to view and participate in private placement financings of public companies. Interested investors are invited to view further details of our current private placement at stockhouse.biomark.co.

President and CEO of BioMark Rashid Ahmed, stated the following regarding Stockhouse Deal Room: "We're utilizing the Stockhouse Deal Room (<http://www.stockhouse.com/dealroom>) in order to offer faster and more economical private placement medium for investors to participate."

About BioMark Diagnostics Inc.

BioMark Diagnostics is developing proprietary, non-invasive, and accurate cancer diagnostic solutions, to help detect, monitor and assess treatment for cancer early and cost effectively. The technology will also be used for measuring response to treatment and potentially for serial monitoring for cancer survivors. For more information please visit the company website at: www.biomarkdiagnostics.com

For further information on BioMark, please Contact:

Rashid Ahmed Bux

President & CEO

BioMark Diagnostics Inc.

Tel. 604-282-6567

Email: info@biomarkdiagnostics.com

Forward-Looking Information:

This press release may include forward-looking information within the meaning of Canadian securities legislation, concerning the business of BioMark. Forward-looking information is based on certain key expectations and assumptions made by the management of BioMark. Although BioMark believes that the expectations and assumptions on which such forward-looking information is based are reasonable, undue reliance should not be placed on the forward-looking information because BioMark can give no assurance that they will prove to be correct. Forward-looking statements contained in this press release are made as of the date of this press release. BioMark disclaims any intent or obligation to update publicly any forward-looking information, whether as a result of new information, future events or results or otherwise, other than as required by applicable securities laws.

This news release does not constitute an offer to sell or a solicitation of an offer to buy any of the securities described herein in the United States. The securities described herein have not been and will not be registered under the United States Securities Act of 1933, as amended, or any applicable securities laws or any state of the United States and may not be offered or sold in the United States or to the account or benefit of a person in the United States absent an exemption from the registration requirements.

The CSE has not reviewed, approved or disapproved the content of this press release.